Skip to content

Public FDA record

Z-1230-2020: ADVIA Chemistry Enzymatic Creatinine (ECRE_2) reagent, SMN 10335869

Recall record Z-1230-2020 for Siemens Healthcare Diagnostics, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1230-2020
Company in FDA record
Siemens Healthcare Diagnostics, Inc.
FDA classification date
Jan 24, 2020
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology.

Source facts

Action
Siemens Healthcare Diagnostics initiated a customer communication for this issue via letter beginning December 18, 2019.
Initiated
2019-12-18
Root cause
Under Investigation by firm
Terminated
2020-06-25
Distribution
US Nationwide
Recall number
Z-1230-2020
Recall status
Terminated
CDRH record ID
178848
FDA classified
2020-01-24
Recall event number
84612

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗